Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Reviews/Commentaries/Position Statements

The Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes

  1. Robert I. Misbin, MD
  1. From the Division of Endocrinology and Metabolism, U.S. Food and Drug Administration, Rockville, Maryland
  1. Address correspondence and reprint requests to Robert I. Misbin, MD, Division of Endocrinology and Metabolism, Food and Drug Administration, 5727 Crawford Dr., Rockville, MD 20851. E-mail: misbinr{at}cder.fda.gov
Diabetes Care 2004 Jul; 27(7): 1791-1793. https://doi.org/10.2337/diacare.27.7.1791
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading
  • COSMIC, Comparative Outcomes Study of Metformin Intervention Versus Conventional Approach
  • FDA, Food and Drug Administration

Metformin is the only biguanide that is available in the U.S. Another biguanide, phenformin, had been used since the 1950s, but was declared an “imminent hazard” in 1976 because of lactic acidosis (1). At the time of its removal from the market, there had been 306 documented cases of phenformin-associated lactic acidosis (2), including 1 fatal and 2 nonfatal cases in the randomized controlled trial of the University Group Diabetes Program (3).

Metformin was marketed as Glucophage by Bristol-Myers Squibb in early 1995, with a boxed warning concerning the risk of lactic acidosis. Metformin had been used widely in Europe for several years, where it had been recognized that the risk of lactic acidosis from metformin was no greater than the risk of hypoglycemia from sulfonylureas (4).

Although the clinical utility of metformin had been recognized in the U.S. (5), its approval was undoubtedly delayed by the specter of phenformin and the lingering concern that metformin might also cause lactic acidosis. The eventual approval of metformin was unusually controversial. Crofford (6) predicted that metformin “will be widely used and will improve the outlook for many patients” with diabetes. But fear of lactic acidosis led the consumer advocacy group Public Citizen (7) to issue the warning: “Do not use Glucophage.”

Based on data from Sweden, it was estimated that the risk of lactic acidosis in patients taking phenformin was ∼10-fold higher than the risk in patients taking metformin. A later report from Sweden (9) concluded that discontinuing metformin in aging patients when they developed renal or cardiovascular disease could further reduce the risk of lactic acidosis. The labeling of Glucophage reflected a belief that metformin had the potential to cause lactic acidosis, but that the risk could be mitigated by careful selection of patients.

To help allay concerns about the safety of metformin, Bristol-Myers Squibb committed to perform a large study (the Comparative Outcomes Study of Metformin Intervention Versus Conventional Approach [COSMIC]), comparing 1 year of treatment with metformin to “usual care” with other antidiabetic agents. The results of this study have recently become available (10). There were no meaningful differences in safety outcomes between the 7,227 patients who received metformin and the 1,505 patients who received usual care. There were no cases of lactic acidosis in either group.

Two large government-supported studies provide an impressive body of evidence to support the safety and effectiveness of metformin (11,12). In addition, several manufacturers other than Bristol-Myers Squibb have performed studies in which a new drug was used in combination with metformin or compared with metformin. Metformin is now indicated for use in combination with every other oral antidiabetic agent and insulin and is the only oral agent available in fixed-dose combinations with other antidiabetic agents. Metformin is also specifically labeled for use in children with type 2 diabetes (13). In none of the studies submitted to the U.S. Food and Drug Administration (FDA) in support of these indications were there any episodes of lactic acidosis.

Salpeter et al. (14,15) reviewed published reports of controlled trials involving metformin that lasted 1 month or more and were reported through November 2002. They found no cases of lactic acidosis in 36,000 patient-years of exposure to metformin and concluded that there was no evidence to support a role for metformin in the development of lactic acidosis.

In contrast to the findings from controlled trials, cases of lactic acidosis continue to be reported in patients taking metformin. Among the first million patients (approximately) to have received metformin in the U.S., there were 47 reports (20 fatal) to the FDA of lactic acidosis. Of these patients, 43 had renal failure (labeled contraindication for metformin) or risk factors for lactic acidosis besides metformin (primarily congestive heart failure) (16). There were only four patients who did not have other risk factors for lactic acidosis when metformin was initially given. In one of these four case subjects, lactic acidosis appears to have been precipitated by an episode of urosepsis. None of these four patients died.

A recent review by Stades et al. (17) provides additional evidence that most cases of metformin-associated lactic acidosis, particularly fatal ones, are related to underlying conditions rather than to metformin. The authors went on to attribute many reports of metformin-associated lactic acidosis to a publication bias in which the widely held clinical impression that metformin causes lactic acidosis is erroneously fortified. I believe that this view is probably correct and cite as an example a report of “lactic acidosis” in a patient whose lactate level was only about 2 mmol/l (18 and see the technical note in the appendix). On the other hand, there is a recent report by Dawson et al. (19) of severe lactic acidosis in a patient without risk factors other than metformin.

Lactic acidosis occurs in nondiabetic patients in association with infection, cancer, liver failure, and renal failure and is almost always a harbinger of death unless the underlying condition is corrected (20,21). In patients with type 2 diabetes, the rate of lactic acidosis is reported (22) to be similar in patients who are taking metformin and in patients who have never taken metformin. Mortality in patients with metformin-associated lactic acidosis appears to be ∼40% and also appears to be associated with heart failure (16,17).

Stacpoole (23) has suggested that reports of metformin-associated lactic acidosis represent “guilt by association” with phenformin. Stades et al. (17) attributed many reports of metformin-associated lactic acidosis to the coincidence that diabetic patients are prone to develop serious medical conditions that lead to lactic acidosis. This view is shared by other authors (24) and is well taken. Patients with high blood levels of metformin appear less likely to die than patients with low levels of metformin, suggesting that lethality was related to the underlying cause (heart failure, hypoxia, etc.) rather than to metformin (17,25). Furthermore, the lack of correlation between lactate levels and metformin levels in these patients (25) strongly suggests that metformin is often an innocent bystander.

The number of documented cases of metformin-associated lactic acidosis is small when one considers how widely metformin is used (17). That metformin has been used safely in patients with contraindications (26–31) can be viewed as evidence that it does not cause lactic acidosis. On the other hand, cases of lactic acidosis from metformin overdoses (32), particularly in young people without risk factors (33,34), suggest that metformin can cause lactic acidosis if given in large doses.

Summary

Metformin rarely, if ever, causes lactic acidosis when it is used as labeled. Metformin is associated with lactic acidosis in patients with conditions that can themselves cause lactic acidosis (heart failure, hypoxia, sepsis, etc.). But it is impossible to determine to what extent, if any, metformin may contribute to the development of lactic acidosis in any individual case. When metformin is used as labeled, the increased risk of lactic acidosis is either zero or so close to zero that it cannot be factored into ordinary clinical decision making. That metformin can itself cause lactic acidosis is supported by the finding of lactic acidosis in people who took overdoses. Thus, the accumulation of metformin in the setting of renal insufficiency might be expected to precipitate lactic acidosis in some patients who are at risk. If one excludes overdoses, most cases of metformin-associated lactic acidosis, particularly the fatal ones, were probably not caused by metformin.

APPENDIX

Technical note

Using venous blood obtained without a tourniquet after 2 h of rest, the upper limit of the 95% CI for plasma lactate was ∼3 mmol/l for patients in COSMIC whether they were taking metformin or not (10). A similar finding was reported by DeFronzo et al. (35). Most authors have used a value of 5 mmol/l as the threshold for the diagnosis of lactic acidosis.

Footnotes

  • The opinions expressed in this commentary are those of the author and do not necessarily reflect the official position of the Food and Drug Administration.

    A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted April 14, 2004.
    • Received March 29, 2004.
  • DIABETES CARE

References

  1. ↵
    Meadows M: Why drugs get pulled off the market [article online], 2002. Available from http://www.fda.gov/fdac/features/2002/102_drug.html.
  2. ↵
    Misbin RI: Phenformin associated lactic acidosis: pathogenesis and treatment. Ann Intern Med 87:591–595, 1977
  3. ↵
    University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complication in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 24 (Suppl. 1):65–184, 1975
    OpenUrlPubMed
  4. ↵
    Campbell I: Metformin and the sulfonylureas: the comparative risk. Horm Metab Res 15 (Suppl.):105–111, 1985
    OpenUrl
  5. ↵
    Colwell JA: Is it time to introduce metformin in the United States? Diabetes Care 16:653–655, 1993
    OpenUrlFREE Full Text
  6. ↵
    Crofford OB: Metformin (Editorial). N Engl J Med 333:588–589, 1995
    OpenUrlCrossRefPubMed
  7. ↵
    Public Citizen: Do not use Glucophage (metformin). Worst Pills, Best Pills 1:5, 1995
    OpenUrl
  8. Bergman U, Boman G, Wiholm BE: Epidemiology of adverse drug reactions to phenformin and metformin. Br Med J 2:464–466, 1978
  9. ↵
    Wiholm BE, Myred M: Metformin-associated lactic acidosis in Sweden 1977–1991. Eur J Clin Pharmacol 44:589–591, 1993
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Cryer DR, Mills DJ, Henry DH, Nicholas SP: Comparative Outcomes Study of Metformin Intervention Versus Conventional Approach: the COSMIC approach study (Abstract). Diabetes 53 (Suppl. 1):A115, 2003
    OpenUrl
  11. ↵
    UK Prospective Diabetes Study Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865, 1998
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403, 2002
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Misbin RI: Placebo-controlled trials in type 2 diabetes (Commentary). Diabetes Care 24:773–774, 2001
    OpenUrlFREE Full Text
  14. ↵
    Salpeter S, Greyber E, Pasternak G, Salpeter E: Risk of fatal and non-fatal lactic acidosis with metformin in type 2 diabetes. Cochrane Database Syst Rev 2:CD002967, 2003
  15. ↵
    Salpeter S, Greyber E, Pasternak G, Salpeter E: Risk of fatal and non-fatal lactic acidosis with metformin in type 2 diabetes. Arch Intern Med 163:2294–2602, 2003
    OpenUrl
  16. ↵
    Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA: Lactic acidosis in patients with diabetes treated with metformin (Letter). N Engl J Med 338:265–266, 1998
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Stades AME, Heikens JT, Erkelens DW, Holleman F, Hoekstra JBL: Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Int Med 255:179–187, 2004
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Pepper GM, Schwartz M: Lactic acidosis associated with Glucophage use in a man with normal renal and hepatic function (Letter). Diabetes Care 20:232–233, 1997
    OpenUrlFREE Full Text
  19. ↵
    Dawson D, Conlon C: Case study: metformin-associated lactic acidosis: could orlistat be relevant? (Letter). Diabetes Care 26:2471–2472, 2003
    OpenUrlFREE Full Text
  20. ↵
    Stacpoole PW, Harman EM, Curry SH, Baumgartner TG, Misbin RI: Treatment of lactic acidosis with dichloroacetate. N Engl J Med 309:390–396, 1983
    OpenUrlPubMedWeb of Science
  21. ↵
    Lactic Acidosis Study Group: Natural history and course of acquired lactic acidosis in adults. Am J Med 97:47–54, 1994
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Brown JB, Pedula K, Barzilay J, Herson MK, Latare P: Lactic acidosis rates in type 2 diabetes. Diabetes Care 21:1659–1663, 1998
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Stacpoole PW: Metformin and lactic acidosis: guilt by association (Editorial). Diabetes Care 21:1587–1588, 1998
    OpenUrlFREE Full Text
  24. ↵
    Jones GC, Macklin JP, Alexander WD: Contraindications to the use of metformin: evidence suggests that it is time to amend the list. BMJ 326:4–5, 2003
    OpenUrlFREE Full Text
  25. ↵
    Lalau JD, Race JM: Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentration. Drug Saf 20:377–384, 1999
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    Sulkin TV, Bosman D, Krentz AJ: Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 20:925–928, 1997
    OpenUrlAbstract/FREE Full Text
  27. Emslie-Smith AM, Boyle DIR, Evans JMM, Sullivan F, Morris AD: Contraindications to metformin in patients with type 2 diabetes: a population-based study on adherence to prescribing guidelines. Diabet Med 18:483–488, 2001
    OpenUrlCrossRefPubMedWeb of Science
  28. Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M, Rothman R: Frequency of inappropriate metformin prescriptions (Letter). JAMA 287:2504–2505, 2002
    OpenUrlCrossRefPubMedWeb of Science
  29. Holstein I, Nahrwold D, Hinze S, Egberts EH: Contra-indications to metformin therapy largely disregarded. Diabet Med 16:692–696, 1999
    OpenUrlCrossRefPubMedWeb of Science
  30. Rachmani R, Slavachevski I, Levy Z, Zadok B, Kedar Y, Ravid M: Metformin in patients with type 2 diabetes: reconsideration of traditional contraindications. Eur J Intern Med 13:428–433, 2002
    OpenUrlCrossRefPubMed
  31. ↵
    Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody J, Krumholz HM: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 290:81–85, 2003
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    Lalau JD, Mourlhon C, Bergeret A, LaCroix C: Consequences of metformin intoxication (Letter). Diabetes Care 21:2036–2037, 1998
    OpenUrlFREE Full Text
  33. ↵
    Chang CT, Chen YC, Fang JT, Huang CC: Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 15:398–402, 2002
    OpenUrlPubMedWeb of Science
  34. ↵
    Medical officer’s review of glucophage overdoses and lactic acidosis. Rockville, MD, Food and Drug Administration, 2004
  35. ↵
    DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 333:541–549, 1995
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 27 (7)

In this Issue

July 2004, 27(7)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes
Robert I. Misbin
Diabetes Care Jul 2004, 27 (7) 1791-1793; DOI: 10.2337/diacare.27.7.1791

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes
Robert I. Misbin
Diabetes Care Jul 2004, 27 (7) 1791-1793; DOI: 10.2337/diacare.27.7.1791
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • APPENDIX
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Managing Preexisting Diabetes for Pregnancy
  • Third Annual World Congress on the Insulin Resistance Syndrome
  • Third Annual World Congress on the Insulin Resistance Syndrome
Show more Reviews/Commentaries/Position Statements

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.